Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 329.89 USD -3.02% Market Closed
Market Cap: 177.6B USD

AMGN's latest stock split occurred on Nov 22, 1999

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

The adjusted shares began trading on Nov 22, 1999. This was AMGN's 5th stock split, following the previous one in Mar 1, 1999.

Last Splits:
Nov 22, 1999
2-for-1
Mar 1, 1999
2-for-1
Aug 16, 1995
2-for-1
Sep 11, 1991
3-for-1
Aug 13, 1990
2-for-1
Pre-Split Price
N/A
Post-Split Price
43.5114
Before
After
Last Splits:
Nov 22, 1999
2-for-1
Mar 1, 1999
2-for-1
Aug 16, 1995
2-for-1
Sep 11, 1991
3-for-1
Aug 13, 1990
2-for-1

Amgen Inc
Stock Splits History

AMGN Stock Splits Timeline
Nov 22, 1999
Nov 22, 1999
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
43.5114
Before
After
Mar 1, 1999
Mar 1, 1999
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
43.5114
Before
After
Aug 16, 1995
Aug 16, 1995
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
43.5114
Before
After
Sep 11, 1991
Sep 11, 1991
Split 3-for-1
x3
Pre-Split Price
N/A
Post-Split Price
43.5114
Before
After
Aug 13, 1990
Aug 13, 1990
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
43.5114
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
47.5 47.5 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
60.6 60.6 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

Amgen Inc
Glance View

Amgen Inc., a towering figure in the biopharmaceutical industry, started its journey in the early 1980s in Thousand Oaks, California, with a visionary commitment to tapping into the potential of recombinant DNA technology. This leap into biotechnology allowed the company to produce vital proteins that the body naturally lacks in certain medical conditions. Concentrating on serious illnesses such as cancer, kidney failure, and rheumatoid arthritis, Amgen transformed itself over the decades from a novel research lab into a global powerhouse, rolling out revolutionary therapies like Epogen and Neulasta. These blockbuster drugs, designed to treat anemia and prevent infections in chemotherapy patients, catapulted Amgen into the echelon of companies that not only evolve with science but also shape its trajectory. Today, Amgen thrives by blending its innovative science with strategic acquisitions, expanding its pipeline beyond merely biological drugs to include biosimilars and small molecule medicines. The company's revenue stream relies heavily on its existing successful therapies while also banking on the future with investments in genetic research and novel drug developments. By leveraging their expertise in biotechnology and clinical trials, Amgen is able to bring new products to market and navigate the complex regulatory landscape efficiently. The firm expertly balances risk and reward, ensuring a steady influx of cash flow through both established product lines and the advent of new therapies. Thus, Amgen, with its robust portfolio and strategic business maneuvers, continues to play a pivotal role in enhancing patient outcomes while reinforcing its position as a leader in the biopharmaceutical realm.

AMGN Intrinsic Value
303.35 USD
Overvaluation 8%
Intrinsic Value
Price
Back to Top